Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd)

注射用重组抗EpCAM和CD3人鼠嵌合双特异性抗体 (武汉友芝友生物制药股份有限公司)

Report date: 2026/05/12 20:00:17

Base Information

Drug NameRecombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd)
Drug Alias NameHumanized recombinant anti-EpCAM and anti-CD3 bispecific antibodyM-701
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-EpCAMAnti-CD3T lymphocytes stimulants +[4] 
TargetsT cell surface glycoprotein CD3Epithelial cell adhesion molecule
Therapy Area/IndicationsSolid tumoursAscitesHydrothorax +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesWuhan Yzy Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChia Tai-Tianqing Runxin Pharmaceutical (Wuhan) Co LtdWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursAscitesHydrothorax +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A